We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Skorpios Trust Sells $27.2 Million of Stoke Therapeutics Stock
Express News | Skorpios Trust Reports 16.9% Stake in Stoke Therapeutics as of Sept 19 Vs 23.4% as of April 17- SEC Filing
Form 144 | Stoke Therapeutics(STOK.US) Insider Proposes to Sell 29.49 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 19, $Stoke Therapeutics(STOK.US)$ Insider Blue Horizon E LTD intends to sell 1.94 million shares of its common stock on Sep 19, with a total market value of approximately $
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Express News | HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
Buy Recommendation for Stoke Therapeutics Backed by STK-001's Promising Therapeutic Impact on Dravet Syndrome
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
Stoke Therapeutics (STOK) Stock Surges on Potential Genetic Treatment Breakthrough
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Buy Rating Affirmed for Stoke Therapeutics Amid Solid Q2 Performance and Regulatory Progress
Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham
Stoke Therapeutics | 10-Q: Q2 2024 Earnings Report
Promising Outlook for Stoke Therapeutics' Zorevunersen as a Disease-Modifying Therapy in Dravet Syndrome